Hospital
Allina Health System
Allina Health System was paid $6.47M by Medicaid between Jan 2018 and Dec 2024, across 71 billing codes. Its largest line is 99283, emergency room visit (moderate) — 52% of everything it billed.
33Billing provider infoALLINA HEALTH SYSTEM
OWATONNA, MN 55060
OWATONNA, MN 55060
33aNPI1528025632assigned 05/01/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.47M
24GClaims72,576
24DCodes billed71
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Minnesota
Rank by total paid#22 of 36
Median peer was paid$11.46M
This provider vs. median0.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,844 | $223K | |
| 2019 | 14,537 | $1.21M | |
| 2020 | 10,776 | $800K | |
| 2021 | 14,808 | $1.23M | |
| 2022 | 11,967 | $1.12M | |
| 2023 | 11,634 | $1.17M | |
| 2024incomplete | 5,010 | $719K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 52% | 16,677 | 15,996 | $3.34M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 7,627 | 7,270 | $2.21M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.1% | 2,245 | 2,126 | $329K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 2.8% | 367 | 347 | $182K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.5% | 1,792 | 1,573 | $100K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 519 | 493 | $57K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,041 | 940 | $55K |
| 80053 | Comprehensive metabolic panel | <1% | 6,549 | 6,154 | $32K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,063 | 1,774 | $28K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 337 | 330 | $20K |
| 71045 | Radiologic examination, chest; single view | <1% | 257 | 244 | $16K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 10,953 | 10,250 | $16K |
59 more codes
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 285 | $16K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 381 | $11K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 34 | $9K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 115 | $5K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 28 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 68 | $4K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 35 | $3K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,521 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 13 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 43 | $3K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,165 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 111 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 105 | $2K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,864 | $1K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 15 | $1K |
| 81001 | <1% | 915 | $1K | |
| 83690 | <1% | 1,053 | $1K | |
| 86140 | <1% | 609 | $954.51 | |
| 97161 | <1% | 15 | $813.16 | |
| 84484 | <1% | 386 | $598.32 | |
| J2704 | Injection, propofol, 10 mg | <1% | 405 | $589.64 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 661 | $367.92 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 523 | $217.42 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 249 | $215.01 |
| 80306 | <1% | 81 | $201.24 | |
| 84703 | <1% | 98 | $191.75 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 70 | $157.54 |
| 83605 | <1% | 180 | $139.38 | |
| 96376 | <1% | 30 | $136.64 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 523 | $131.72 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 342 | $114.12 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 115 | $102.26 |
| 82077 | <1% | 65 | $97.48 | |
| 88304 | <1% | 14 | $68.79 | |
| 84145 | <1% | 12 | $61.92 | |
| 83735 | <1% | 59 | $60.77 | |
| 81003 | <1% | 164 | $59.62 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 112 | $53.43 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 76 | $37.21 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 14 | $35.54 |
| 85610 | <1% | 58 | $35.31 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 25 | $29.55 |
| A9270 | Non-covered item or service | <1% | 30 | $3.30 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 39 | $0.08 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,135 | $0.01 |
| 87081 | 0% | 14 | $0.00 | |
| 84512 | 0% | 16 | $0.00 | |
| 87807 | 0% | 29 | $0.00 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 0% | 16 | $0.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0% | 17 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 40 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 14 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 35 | $0.00 |
| 85027 | 0% | 29 | $0.00 | |
| 84443 | Thyroid stimulating hormone (TSH) | 0% | 18 | $0.00 |
| 81025 | 0% | 36 | $0.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 0% | 17 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialJOHNSTON, MICHAEL (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Decatur County Hospital | Leon, IA | $596K |
| Michael Johnston LLC | Stonewall, LA | $415K |
| Decatur County Hospital | Leon, IA | $36K |
| N & J Optical Supply INC | Harlan, IA | $180.60 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.